Dana Ascherman is a Rheumatology/Immunology physician. OpenAlex indexes 131 publications with 5,371 citations (h-index 35).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1475 NW 12th Ave
Miami, FL 331361002
Telephone
305-243-7545Registry record last updated 26 Feb 2013.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Boehringer Ingelheim Pharmaceuticals, Inc.Program year202413 payments
- Sandoz Inc.Program year20221 payment
- EMD Serono, Inc.Program year20211 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
31.3%Nonsteroidal Anti-inflammatory Drug9%Celecoxib100%Part D≥14 patientsFolate Analog Metabolic Inhibitor8%Methotrexate100%Part D≥16 patients+ 5 more classes in this area
Antiparasitic
23.1%Antimalarial23.1%Hydroxychloroquine Sulfate100%Part D≥28 patientsNervous system
16.1%Gabapentinoids5.6%Gabapentin100%Part D<11 patientsOpioid Agonist5.3%Tramadol Hcl100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
3 NIH research awards on record, funded 2010–2018 per NIH RePORTER. The latest:
- Innate Immune Activation in Autoimmune Myopathy
University of Miami School of Medicine
FY2018$356,528R01AR071369 - Innate Immune Activation in Autoimmune Myopathy
University of Miami School of Medicine
FY2017$380,027R01AR071369 - Peripheral Blood Biomarkers of RA-associated Interstitial Lung Disease
Miami Va Health Care System
FY2014I01BX000788
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Genetic, social, and environmental risk factors in rheumatoid arthritis-associated interstitial lung disease
Seminars in Arthritis and Rheumatism
2022
Similar KOLs
Other experts from the same institution or the same specialty.
David J. Hunter
The University of Sydney
Aziz Sheikh
Universiti Malaysia Terengganu
Nima Hafezi‐Nejad
The University of Sydney
Gelin Xu
Second Affiliated Hospital of Nanjing Medical University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”